scholarly journals Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India

PLoS ONE ◽  
2011 ◽  
Vol 6 (12) ◽  
pp. e28066 ◽  
Author(s):  
Petros Isaakidis ◽  
Helen S. Cox ◽  
Bhanumati Varghese ◽  
Chiara Montaldo ◽  
Esdras Da Silva ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
Tuberculosis Treatment ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis

scholarly journals The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review

2021 ◽  
Vol 26 ◽  
Author(s):  
Lisa Singh ◽  
Lehlohonolo J. Mathibe ◽  
Varsha Bangalee
Keyword(s):  
Treatment Outcomes ◽  
Scoping Review ◽  
Drug Regimen ◽  
Global Scale ◽  
Oral Drug ◽  
Drug Resistant ◽  
Treatment Rate ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis

Background: Drug-resistant tuberculosis (DR-TB) has become a serious cause of concern both on a global scale and in South Africa. It is associated with a lower successful treatment rate, thus creating a hurdle in achieving good treatment outcomes for patients.Aim: The aim of this study was to compare the efficacy of the drug kanamycin, an injectable aminoglycoside, to bedaquiline, a newer oral drug used to treat DR-TB.Methods: PubMed and Google Scholar, both of which are online databases, were extensively searched using the necessary keywords so that studies that were relevant to the scoping review were retrieved. A data-charting list was developed to extract the needed data for this scoping review.Results: The main findings of the scoping review showed that bedaquiline was highly efficacious in the treatment of DR-TB, and that it was a valuable addition in the treatment of DR-TB. The findings of the study also showed that kanamycin does not have good efficacy against DR-TB. and its use extends the treatment of DR˗TB.Conclusion: It stands to reason that bedaquiline replaces kanamycin in the DR-TB drug regimen as it was shown to be more efficacious and patients experienced better treatment outcomes in a shorter period of time. There were also fewer adverse effects associated with bedaquiline as compared to kanamycin.Contribution: Bedaquiline-based DR-TB therapy is more efficacious than aminoglycoside-based regimens which include kanamycin.

Sign in / Sign up

Export Citation Format

Share Document